Astrazeneca (AZN) Other Accumulated Expenses (2016 - 2026)

Astrazeneca has reported Other Accumulated Expenses over the past 17 years, most recently at -$2.2 billion for Q1 2026.

For Q1 2026, Other Accumulated Expenses fell 5.74% year-over-year to -$2.2 billion; the TTM value through Mar 2026 reached -$2.2 billion, down 5.74%, while the annual FY2025 figure was -$2.4 billion, 34.41% down from the prior year.
Other Accumulated Expenses for Q1 2026 was -$2.2 billion at Astrazeneca, up from -$2.4 billion in the prior quarter.
Over five years, Other Accumulated Expenses peaked at -$1.6 billion in Q2 2025 and troughed at -$4.9 billion in Q3 2022.
A 5-year average of -$2.7 billion and a median of -$2.4 billion in 2025 define the central range for Other Accumulated Expenses.
Biggest five-year swings in Other Accumulated Expenses: soared 54.04% in 2023 and later plummeted 34.41% in 2025.
Year by year, Other Accumulated Expenses stood at -$4.3 billion in 2022, then skyrocketed by 37.7% to -$2.7 billion in 2023, then soared by 33.46% to -$1.8 billion in 2024, then plummeted by 34.41% to -$2.4 billion in 2025, then grew by 9.42% to -$2.2 billion in 2026.
Business Quant data shows Other Accumulated Expenses for AZN at -$2.2 billion in Q1 2026, -$2.4 billion in Q4 2025, and -$2.0 billion in Q3 2025.

Peer Comparison